Login to Your Account

Plexxikon, Roche Opening EAP

PLX4032 Shines in Phase II; Possible Early Approval?

By Jennifer Boggs

Monday, November 8, 2010
Plexxikon Inc.'s and Roche AG's melanoma drug PLX4032 (RG7204) continued its streak of stellar data, with results from an open-label Phase II trial showing a 52 percent response rate in patients with previously treated disease with the BRAF V600E mutation, and the companies are planning to open an access program to answer growing patient demand for the drug ahead of approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription